CVRx news
MINNEAPOLIS, July 12, 2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world`s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which was approved by the U.S. Food and Drug Administration (FDA) earlier this year.
The second-generation programmer has a modernized design, operates on an upgraded cellular network that enables remote view access, and includes an improved user interface that simplifies im
MINNEAPOLIS, June 10, 2021 - CVRx©. developer of the world`s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF). announced the completion of the first clinical procedure with the company`s new lead implantation approach. The novel ultrasound-guided technique is the latest advancement of
CVRx`s Barostim™ Baroreflex Activation Therapy (BAT™) to treat the symptoms of HF patients. The new approach further simplifies the implant procedure
MINNEAPOLIS, MAY 9,2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world`s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim System.
The Barostim System now includes instructions to allow for safe MRI scans of the head and lower extremities, meaning heart failure patients implanted with Barostim have more diagnostic
MINNEAPOLIS, Nov. 2, 2020 - CVRx®, developer of the world`s first FDA-approved neuromodulation device to treat chronic heart failure (HF), announces that its BAROSTIM NEO™ implantable device has received the Centers for Medicare & Medicaid Services (CMS) inpatient New Technology Add-On Payment (NTAP). Additionally, CMS proposed national coverage determination (NCD) for Breakthrough designation treatments like BAROSTIM NEO.
Effective October 1, 2020, and for a three-year
MINNEAPOLIS, July 21, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced that the BeAT-HF phase III randomized clinical trial has completed enrollment in the post-market phase. CVRx has also enrolled the first patient in a heart failure (“HF”) registry which is designed to be a national repository of individual patient data from commercial BAROSTIM NEO™ cases.
The results of 264 randomized patients in the